 |
Perfosfamide |
|---|---|
| Trade Name | Pergamid |
| Orphan Indication | For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia |
| USA Market Approval | USA |
| USA Designation Date | 1989-12-04 00:00:00 |
| Sponsor | Scios Nova, Inc.;2450 Bayshore Parkway;Mountain View, California, 94043 |
